Viemed Healthcare logo
Viemed Healthcare VMD
$ 9.35 1.58%

Annual report 2025
added 03-04-2026

report update icon

Viemed Healthcare Financial Ratios 2011-2026 | VMD

Annual Financial Ratios Viemed Healthcare

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

23.6 31.2 34.9 56.5 20.0 10.4 24.2 - - - - - - - -

P/S

1.3 1.6 2.0 2.5 1.6 2.5 2.6 - - - - - - - -

EPS

0.4 0.3 0.3 0.2 0.2 0.8 0.2 0.2 - - - - - - -

EV (Enterprise Value)

395 M 377 M 386 M 355 M 178 M 328 M 231 M 8.08 M 13.9 M 11.8 M - - - - -

EBITDA per Share

1.33 1.12 0.94 0.62 0.58 0.646 0.262 - - - - - - - -

EV/EBITDA

6.7 12.1 20.4 - - - - - - - -

PEG

- 0.04 -1.63 - - - - - - - -

P/B

2.5 2.6 3.1 3.6 1.9 4.0 4.7 - - - - - - - -

P/CF

6.8 9.0 7.9 12.7 8.1 14.9 36.1 - - - - - - - -

ROE %

10.55 8.57 8.99 6.41 9.62 38.60 19.51 - - - - - - - -

ROA %

7.50 6.36 6.61 5.32 7.74 28.01 10.32 - - - - - - - -

ROCE %

14.70 12.99 11.67 8.40 11.56 27.31 16.27 - - - - - - - -

Current Ratio

3.6 4.0 3.8 5.9 5.1 2.0 1.1 - - - - - - - -

DSO

34.1 35.3 33.7 37.1 39.3 34.4 52.5 - - - - - - - -

DIO

14.9 17.9 21.3 20.3 19.9 16.5 20.5 - - - - - - - -

DPO

20.1 19.0 17.7 19.8 22.3 23.9 86.1 - - - - - - - -

Operating Cycle

49.0 53.2 55.0 57.4 59.2 50.9 72.9 - - - - - - - -

Cash Conversion Cycle

28.9 34.2 37.3 37.5 36.9 27.0 -13.2 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Viemed Healthcare

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.09 0.08 0.07 - 0.1 0.04 0.04 - 0.08 0.06 0.04 - 0.03 0.02 0.04 - 0.05 0.04 0.04 0.13 0.07 0.5 0.11 0.06 0.08 0.04 0.05 0.08 0.06 0.05 0.06 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

0.16 0.14 0.27 - 0.15 0.1 0.22 - 0.12 0.08 0.18 - 0.33 0.03 0.14 - 0.28 0.07 0.1 0.13 0.28 0.44 0.18 0.07 0.17 0.12 0.1 0.08 0.13 0.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

9.90 10.32 9.28 5.65 8.33 7.96 8.97 6.43 7.55 5.99 4.80 4.00 6.00 6.88 7.65 5.84 12.04 13.47 35.42 38.60 37.85 40.95 20.22 19.51 23.16 22.96 25.92 30.42 21.31 14.97 8.99 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

7.21 7.76 6.94 4.22 6.17 5.84 6.51 4.73 5.62 4.55 4.46 3.84 5.39 4.58 5.99 4.45 8.96 9.90 25.73 28.01 26.40 27.36 11.72 10.32 12.96 13.65 15.97 19.07 13.53 9.39 5.47 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

14.07 14.69 13.92 8.73 12.29 11.63 11.37 7.95 9.43 7.35 5.96 4.78 7.84 9.42 11.22 7.40 13.28 14.73 26.22 29.91 28.77 28.12 16.69 15.63 19.43 22.45 25.77 30.68 22.12 15.25 8.99 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

3.0 4.3 4.3 4.0 4.0 3.8 4.0 3.8 3.7 3.3 5.1 5.9 4.7 - 5.2 5.1 4.4 4.5 3.8 3.6 3.6 3.6 3.6 2.1 2.1 2.1 2.1 2.5 2.9 2.9 2.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

34.2 38.6 39.9 - 42.6 42.8 38.7 - 33.1 36.0 36.6 - 19.1 18.6 37.4 - 38.7 42.3 41.2 36.2 33.8 26.4 45.8 49.1 51.7 51.8 51.3 43.9 47.6 58.6 34.9 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

14.3 15.3 15.6 - 16.9 18.1 19.7 - 22.1 21.0 20.6 - 10.3 8.8 18.1 - 21.7 22.3 19.4 - 15.1 12.4 20.3 - 19.6 21.8 38.4 54.4 64.2 52.8 25.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

25.3 28.1 23.4 - 23.8 25.1 21.9 - 29.4 27.7 20.3 - 12.1 13.1 25.3 - 30.1 23.3 19.8 - 13.7 11.3 37.6 - 67.9 75.4 95.8 110.8 130.9 94.5 35.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

48.6 53.9 55.5 - 59.4 60.9 58.4 - 55.2 57.0 57.2 - 29.4 27.5 55.5 - 60.4 64.6 60.5 36.2 48.8 38.8 66.1 49.1 71.3 73.6 89.8 98.3 111.9 111.4 60.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

23.3 25.8 32.1 - 35.6 35.8 36.5 - 25.8 29.4 36.9 - 17.3 14.4 30.2 - 30.3 41.3 40.8 36.2 35.1 27.5 28.5 49.1 3.4 -1.8 -6.0 -12.5 -19.0 16.9 24.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Viemed Healthcare, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Penumbra Penumbra
PEN
$ 335.76 0.45 % $ 13.1 B usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 221.53 -1.76 % $ 15.6 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 5.73 11.26 % $ 180 M canadaCanada
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 4.0 4.71 % $ 171 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 3.97 3.39 % $ 111 M australiaAustralia
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 36.75 0.45 % $ 1.14 B usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 2.6 1.17 % $ 7.21 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Electromed Electromed
ELMD
$ 24.89 0.77 % $ 210 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 32.38 0.67 % $ 23.8 B britainBritain
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Sensus Healthcare Sensus Healthcare
SRTS
$ 4.23 6.82 % $ 69.1 M usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.13 - $ 610 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.69 -1.55 % $ 37.6 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 2.29 5.9 % $ 3.57 M usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 27.7 3.13 % $ 634 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
TELA Bio TELA Bio
TELA
$ 0.7 -8.05 % $ 16 M usaUSA
Orthofix Medical Orthofix Medical
OFIX
$ 11.82 0.81 % $ 468 M curacaoCuracao
InspireMD InspireMD
NSPR
$ 1.78 -0.84 % $ 114 M israelIsrael
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 24.17 -1.41 % $ 1.64 B usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 11.42 -0.52 % $ 1.54 B usaUSA
Myomo Myomo
MYO
$ 0.7 -0.27 % $ 29.3 M usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 2.33 -3.13 % $ 137 M israelIsrael
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.7 -5.37 % $ 138 M franceFrance
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 16.3 2.45 % $ 382 M usaUSA
Outset Medical Outset Medical
OM
$ 3.48 -1.45 % $ 52.9 K usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 51.73 -0.67 % $ 1.52 B usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.3 -1.15 % $ 52.9 M usaUSA